Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifampridine Phosphate in LEMS
NCT01377922Phase 3Completed
- Start
- Jun 2011
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Lambert-Eaton myasthenic syndrome (LEMS) comparing Amifampridine Phosphate with Placebo (2 arms). Primary endpoints: Quantitative Myasthenia Gravis at 14 days and Subject Global Impression at 14 days. Started Jun 2011; status: completed.
02
Drugs
amifampridine
03
Conditions
Lambert-Eaton myasthenic syndrome (LEMS)
Beyond the preview
Go deeper on NCT01377922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01377922.